IMS 2022 | Evaluating the impact of screening on survival in AL amyloidosis
Sandy Wong
• 26 Aug 2022
Sandy Wong, MD, University of California, Los Angeles, CA, discusses the design and aims of a study evaluating whether screening can improve survival in AL amyloidosis. In this study, patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma will have their light chains sequenced in order to identify light chains associated with the development of systemic AL amyloidosis early and prevent progression to advanced stages of the disease. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
